胰腺癌治疗抵抗的生物学基础。
The biological underpinnings of therapeutic resistance in pancreatic cancer.
机构信息
Abramson Cancer Center; University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
出版信息
Genes Dev. 2021 Jul 1;35(13-14):940-962. doi: 10.1101/gad.348523.121. Epub 2021 Jun 11.
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.
胰腺导管腺癌（PDAC）是美国癌症相关死亡的主要原因，直到最近才达到 5 年生存率 10%。这一惨淡的预后反映了 PDAC 有效适应和抵抗治疗干预的显著能力。在这篇综述中，我们讨论了我们对 PDAC 生物学基础的理解的最新进展及其作为这种高度致命疾病的可靶向弱点的意义。
Zotero 插件